Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma

NCT02023593 is registered in ClinicalTrials.gov with Yuhong Li as lead sponsor.

NCT NCT02023593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02023593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma
Lead sponsor
Yuhong Li
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
December 31, 2022
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal carcinoma